New pill plus immunotherapy takes on tough melanoma
Disease control
Recruiting now
This study tests a new drug, LNS8801, taken as a daily pill, either alone or with the immunotherapy pembrolizumab, in people with advanced melanoma that has not responded to prior treatments. About 135 participants will be randomly assigned to one of three groups: LNS8801 alone, …
Phase: PHASE2, PHASE3 • Sponsor: Linnaeus Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC